Jorge Cortez, "A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph+) Leukemias Including Patients with T315I Mutation." ASH, San Diego, CA 2011.
Presentations by Research Collaborators
For more information or copies of Deciphera presentations, contact us at 785.830.2100 or info@deciphera.com.
-
12.2011
-
12.2011
Neil Shah and Kapil N.Bhalla, "Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT3-ITD or FLT3 Kinase Domain Mutations", ASH, San Diego, CA 2011.
-
12.2011
Dean D. Metcalfe and Todd M. Wilson, "Targeting the KIT Activating Switch Control Pocket: A Novel Mechanism to Inhibit Mast Cell Activation and KIT D816V Neoplastic Mast Cell Proliferation.", ASH, San Diego, CA 2011.
-
11.2010
Jonathan Fletcher, “Molecular Heterogeneity of Kinase Inhibitor Resistance Mechanisms in Gastrointestinal Stromal Tumors.” Connective Tissue Oncology Society, Paris, France 2010.
-
06.2010
Richard Van Etten, “New Ways to Block an Old Target: Allosteric Tyrosine Kinase Inhibitors.” Hematology In Focus, 15th Congress of EHA, Barcelona, Spain 2010.
-
06.2010
Moshe Talpaz, “Therapy for CML: What is the Best TKI? When? And Beyond?” ASCO, Chicago, IL 2010.
-
06.2010
Michael Heinrich, “In Vitro Activity of Novel KIT/PDGFRα Switch Pocket Kinase Inhibitors Against Mutations Associated with Drug-Resistant GIST.” ASCO, Chicago, IL 2010.
-
06.2010
Carlo Gambacorti-Passerini, “A New BCR-ABL Mutation (L248R) Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, is Sensitive to the Switch Pocket Inhibitor DCC-2036.” ASCO, Chicago, IL 2010.
-
06.2010
Ann Gramza, “Activity of Novel RET Inhibitors Against RET Genotypes Associated with Medullary Thyroid Cancer.” ASCO, Chicago, IL 2010.
-
12.2009
Moshe Talpaz, “CML- After a Decade of Imatinib: “Resistance and New Agents”.” ASH, New Orleans, LA 2009.
-
12.2009
Jorge Cortes, “Emerging Strategies for the Treatment of CML.” ASCO, Orlando, FL 2009.
-
12.2008
Richard Van Etten, “Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I.” ASH, San Francisco, CA 2008.